Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET

Company Participants

Karina Calzadilla - Vice President of Investor Relations

Chad Robins - Co-founder, Chairman & Chief Executive Officer

Tycho Peterson - Chief Financial Officer

Nitin Sood - Chief Commercial Officer, MRD

Sharon Benzeno - Chief Commercial Officer, Immune Medicine

Conference Call Participants

Mark Massaro - BTIG

David Westenberg - Piper Sandler

Derik De Bruin - Bank of America

Yuko Oku - Morgan Stanley

Tom Stevens - Cowen & Company

Dustin Scaringe - William Blair

Elizabeth Webster - Goldman Sachs

Dan Leonard - Credit Suisse

Operator

Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2023 Conference Call. [Operator Instructions]

I would now like to hand the conference over to one of your speakers for today, Karina Calzadilla, Head of Investor Relations. Please go ahead.

Karina Calzadilla

Thank you, Britney, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies first quarter 2023 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial results for the first quarter of 2023. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and we'll be referencing to a slide presentation that has been posted to the Investor section in our corporate website.

During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation. In addition, non-GAAP financial measures will be discussed during this call, and a reconciliation from non-GAAP to GAAP metrics can be found in our earnings release.

Joining the call today are Chad Robins, our CEO and Co-founder; and Tycho Peterson, our Chief Financial Officer. In addition, Harlan Robins, Adaptive's Chief Scientific Officer and Co-founder; Nitin Sood, Head of the MRD business; and Sharon Benzeno, Head of the Immune Medicine business will be also available for Q&A.

With that, I'll turn the call over to Chad Robins. Chad?

Chad Robins

Thanks, Karina. Good afternoon, everybody, and thank you for joining us on our first quarter 2023 earnings call. First, I want to thank all our Adaptive employees for their continued dedication and execution. This quarter's results represent a solid start to the year, laying the foundation for us to deliver on our 2023 annual goals.